Basis of Presentation (Details) $ / shares in Units, $ in Thousands		6 Months Ended
	Feb. 20, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) numberOfDays $ / shares shares	Jun. 19, 2020 USD ($)	Dec. 31, 2019 $ / shares
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.01		$ 0.01
Contingent consideration liabilities(1) | $		$ 16,300
Business combination, consideration transferred, equity interests issued (in shares)		26,844,877
Business combination common stock under contingent value right (in shares)		86,630,633
Shares available for future issuance (in shares)		4,211,290
Restored working days | numberOfDays		5
Restored salaries		100.00%
Maximum
Business Acquisition [Line Items]
No of working days | numberOfDays		5
Reduction Of Salaries		75.00%
Minimum
Business Acquisition [Line Items]
No of working days | numberOfDays		4
Reduction Of Salaries		20.00%
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0013
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares to be received from acquisition conversion (in shares)	0.31
Percentage of net sales, contingent consideration	40.00%
Contingent consideration liabilities(1) | $			$ 3,700
Percentage of total contingent consideration under CVRs	19.90%
Business combination contingent value right of total consideration | $	$ 100,000
Business combination, common stock per share exercise price not to exceeded (in dollars per share) | $ / shares	$ 4.42
Business combination stock options assumed in the money (in shares)	34,000
Business combination stock options assumed out of the money (in shares)	6,507,342
Progenics | Cash Payments 2022
Business Acquisition [Line Items]
Contingent consideration liabilities(1) | $	$ 100,000
Progenics | Cash Payments 2023
Business Acquisition [Line Items]
Contingent consideration liabilities(1) | $	$ 150,000